Sign in Subscribe
Cancer

Adverse Drug Reactions: Common Dermatologic Events in CD19 CAR T-Cell Therapy

Strategic Insights

— 1 min read

Patients undergoing CD19 CAR T-cell therapy for B-NHL and ALL experienced a significant number of dermatologic adverse events (dAEs), with 82 patients out of 193 experiencing at least one dAE within the first 100 days post-therapy. Common dAEs included rash, infection, and xerosis, with specific early onset dAEs such as rash and chemotherapy-related events like alopecia and mucositis.

Key Takeaways:

  • A retrospective analysis of 193 patients undergoing CD19 CAR T-cell therapy at Memorial Sloan-Kettering Cancer Center identified 94 dAEs within the first 100 days post-therapy (incidence: 0.42, 95% CI: 0.36-0.51).
  • Common dAEs were rash (30.9%, n = 29), infection (23.4%, n = 22), and xerosis (16.0%, n = 15).
  • Specific early onset dAEs included rash and chemotherapy-related events, eg, alopecia, mucositis (median 12- and 17-days postinfusion, respectively).
  • Thrombocytopenic purpura and xerosis presented later (median 22-and 25-days).
  • CRS and dAEs occurred in 33.5% of patients, with CRS preceding dAEs in 86% of cases.
  • ICANS and dAEs occurred in 15% of patients, with ICANS being antecedent in 67% of cases.
  • DAEs following CAR T-cell therapy are common but mostly low-grade and often manifest within the initial month postinfusion.

Statistics:

  • 82 patients out of 193 (42.5%) experienced at least one dAE within the first 100 days post-therapy.
  • 94 dAEs occurred within the first 100 days post-therapy (incidence: 0.42, 95% CI: 0.36-0.51).
  • 30.9% of patients experienced a rash (n = 29).
  • 23.4% of patients experienced an infection (n = 22).
  • 16.0% of patients experienced xerosis (n = 15).

Sources:

  • Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia, 2025.
  • NewsRx. New Findings from Memorial Sloan-Kettering Cancer Center in the Area of Adverse Drug Reactions Reported (Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies). Cancer Weekly. November 4, 2025; p 359.

Read more